Trials / Completed
CompletedNCT01156090
A Retrospective Cohort Study of Infusion Reactions Due to Vectibix
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 141 (actual)
- Sponsor
- SCRI Development Innovations, LLC · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to identify approximately 100 - 150 patients who have received Vectibix (Panitumumab) in offices and clinics located in Tennessee, North Carolina, South Carolina, and North Georgia from February 2004 - April 2009. Information regarding the incidence and severity of hypersensitivity infusion reactions to Vectibix (Panitumumab)will be captured. In patients who experienced hypersensitivity reactions, the following information will also be collected: premedication, treatment cycle symptoms that were experienced during chemotherapy, changes required in subsequent Vectibix (Panitumumab) or chemotherapy treatment, and outcome of the hypersensitivity reaction.
Conditions
Timeline
- Start date
- 2010-06-01
- Primary completion
- 2012-12-01
- Completion
- 2013-01-01
- First posted
- 2010-07-02
- Last updated
- 2015-08-28
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01156090. Inclusion in this directory is not an endorsement.